Generic placeholder image

Current Traditional Medicine

Author(s): Pugazhenthan Thangaraju*, Sajitha Venkatesan, Meenalotchini Prakash Gurunthalingam, Hemasri Velmurugan, Sree Sudha TY, Thangadurai K, Eswaran Thangaraju and Mahesh Kumar Balasundaram

DOI: 10.2174/2215083810666230411093851

DownloadDownload PDF Flyer Cite As
Complementary Medication for COVID-19 Outbreak Concerns in the Leprosy Community - A Passionate Proposal

Article ID: e110423215648 Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

The number of COVID-19-positive cases continues to climb, causing alarm around the world. The Nilavembu (Andrographis paniculata) Kudineer of Siddha medicine, an alternative medicine practiced in India, has already been shown to be beneficial in viral outbreaks like Chikungunya and Dengue fever. Several investigations have demonstrated that these herbs have anti-inflammatory, analgesic, antipyretic, antibacterial, and antiviral activities against the Herpes simplex virus and Ebstein Barr virus. This herbal remedy has also been shown to have a low risk of negative side effects. There is currently no approved pharmaceutical treatment for COVID-19. Using the phrases 'COVID-19,' 'Ayush,' 'Siddha,' and 'Leprosy,' we searched other databases such as Google, Embase, ScienceDirect, and the Clinical Trial Registry of India. In another research on Siddha treatment, Kabasura Kudineer, a decoction of 15 herbal items was discovered to have activity against the spike protein of SARS COV-2 using an in-silico compound method. As there are no effective treatments available for the prevention and treatment of mild to moderate cases, these two medicines, Nilavembu Kudineer, and Kabasura Kudineer can be used as part of a COVID-19 prophylaxis using a combination of modern and alternative medicine.

Graphical Abstract

[1]
India COVID-19 Status [Online]. Available from: https://www.mohfw.gov.in/ [Accessed on: 7 Sep 2020].
[2]
WHO guidelines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ (Accessed on: 7 Sep 2020).
[3]
ICMR guidelines. Available from: https://www.icmr.nic.in/content/covid-19-guidelines-vrdl-network-and-list-state-nodal-vrdls on 07/09/2020 (Accessed on: 7 Sep 2020).
[4]
Thangaraju P, Arulmani M, Venkatesan S, Gurunthalingam M, Thangaraju E. COVID-19 and leprosy-hurdles and possible solutions. Asian Pac J Trop Med 2020; 13(10): 472-3.
[http://dx.doi.org/10.4103/1995-7645.291042]
[5]
Clinical Trial Registry Data. Available from: http://ctri.nic.in/Clinicaltrials/pubview.php (Accessed on: 10 Sep 2020).
[6]
3 Drug Regimen. Available from: https://timesofindia.indiatimes.com/city/jaipur/city-docs-cure-corona-patient-with-hiv-drugs/articleshowprint/74584859.cms(Accessed on: 10 Sep 2020).
[7]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4): 105932.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[8]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]
[9]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[10]
Clinical Trial Data. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19&Search=Apply&age_v=&gndr=&type=&rslt= (Accessed on 9 Sep 2020).
[11]
WHO Management. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (Accessed on 9 Sep 2020).
[12]
WHO Blueprint?. Available from: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 (Accessed on: 9 Sep 2020).
[13]
Hydroxychloroquine Prophylaxis Available from: https://www.mohfw.gov.in/pdf/Revisedadvisoryontheuseofhydrox ychloroquineasprophylaxisforSARSCOVID19infection.pdf (Accessed on: 9 Sep 2020).
[14]
Polycarpou A, Walker SL, Lockwood DNJ. A systematic review of immunological studies of erythema nodosum leprosum. Front Immunol 2017; 8: 233.
[http://dx.doi.org/10.3389/fimmu.2017.00233] [PMID: 28348555]
[15]
Sinha S, Sardana K, Sachdeva S. Hydroxychloroquine in dermatology and beyond: Recent update. Indian Dermatol Online J 2020; 11(3): 453-64.
[http://dx.doi.org/10.4103/idoj.IDOJ_280_20] [PMID: 32695719]
[16]
Ministry of AYUSH Advisory. Available from: https://pib.gov.in/newsite/ (Accessed on: 9 Sep 2020).
[17]
Lavekar G, Padhi M. Management of chikungunya through ayurveda and siddha: A technical report. (1st ed.), New Delhi: Central Council for Research in Ayurveda and Siddha 2007.
[18]
Parthiban P, Kumar V. Siddha medicine and clinical presentation of dengue fever at tertiary care hospital of Chennai, Tamil Nadu, India. Int J Adv Ayurveda Yoga Unani Siddha Homeopathy 2014; 3: 209-12.
[19]
Jain J, Nayak K, Tanwar N, et al. Clinical, serological, and virological analysis of 572 chikungunya patients from 2010 to 2013 in India. Clin Infect Dis 2017; 65(1): 133-40.
[http://dx.doi.org/10.1093/cid/cix283] [PMID: 28379375]
[20]
Rajasekaran A, Arivukkarasu R, Mathew L. A systematic comprehensive review on therapeutic potential of Andrographis paniculata (Burm. f.) Wall. Ex Nees. J Pharmacogn Phytochem 2016; 5: 189.
[21]
Jain J, Kumar A, Narayanan V, et al. Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation. J Ayurveda Integr Med 2020; 11(3): 329-35.
[http://dx.doi.org/10.1016/j.jaim.2018.05.006] [PMID: 30685096]
[22]
Jiang X, Yu P, Jiang J, et al. Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur J Med Chem 2009; 44(7): 2936-43.
[http://dx.doi.org/10.1016/j.ejmech.2008.12.014] [PMID: 19152987]
[23]
Ahmed QU, Samah OA, Sule A. Andrographis paniculata (Burm. f) Wall. ex Ness: A potent anti-bacterial plant. Intech Antimicrobial agents 2010; 17: 346-60.
[24]
Kunwar RM, Shrestha KP, Bussmann RW. Traditional herbal medicine in Far-west Nepal: A pharmacological appraisal. J Ethnobiol Ethnomed 2010; 6(1): 35.
[http://dx.doi.org/10.1186/1746-4269-6-35] [PMID: 21144003]
[25]
Chang RS, Ding L, Gai-Qing C, Qi-Choa P, Ze-Lin Z, Smith KM. Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus. Exp Biol Med 1991; 197(1): 59-66.
[http://dx.doi.org/10.3181/00379727-197-43225] [PMID: 1708503]
[26]
Tang LIC, Ling APK, Koh RY, Chye SM, Voon KGL. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complement Altern Med 2012; 12(1): 3.
[http://dx.doi.org/10.1186/1472-6882-12-3]
[27]
Lin TP, Chen SY, Duh PD, Chang LK, Liu YN. Inhibition of the epstein-barr virus lytic cycle by andrographolide. Biol Pharm Bull 2008; 31(11): 2018-23.
[http://dx.doi.org/10.1248/bpb.31.2018] [PMID: 18981566]
[28]
Siti Najila MJ, Noor Rain A, Mohamad Kamel AG, et al. The screening of extracts from Goniothalamus scortechinii, Aralidium pinnatifidum and Andrographis paniculata for anti-malarial activity using the lactate dehydrogenase assay. J Ethnopharmacol 2002; 82(2-3): 239-42.
[http://dx.doi.org/10.1016/S0378-8741(02)00183-6] [PMID: 12242001]
[29]
Walter TM, Justinraj CS. , NVS. Effect of nilavembu kudineer in the prevention and management of COVID-19 by inhibiting ACE2 Receptor. Siddha papers. 2020.
[30]
Chang HM, But PPH, Eds. Pharmacology and applications of Chinese materia medica Vol 1,. Singapore: World Scientific 1986; pp. 918-28.
[http://dx.doi.org/10.1142/0284]
[31]
Guidelines for Siddha Practitioners for COVID-19 2020. Available from: https://www.ayush.gov.in/docs/siddha-guidelines.pdf (Accessed on: 9 Sep 2020).
[32]
Kumar MP, Sundaram KM, Ramasamy MS. Coronavirus Spike (S) Glycoprotein (2019-Ncov)targeted siddha medicines kabasura kudineer and thonthasura kudineer in silico evidence for corona viral drug. Asian J Pharm Res Health Care 2020; 12(1): 20-7.
[http://dx.doi.org/10.18311/ajprhc/2020/25103]
[33]
Jayaraj JM, Jothimani M, Palanisamy CP, et al. Computational study on the inhibitory effect of natural compounds against the SARS-CoV-2 proteins. Bioinorg Chem Appl 2022; 2022: 1-19.
[http://dx.doi.org/10.1155/2022/8635054] [PMID: 35340421]
[34]
Kiran G, Karthik L, Shree Devi MS, et al. In silico computational screening of Kabasura Kudineer - Official siddha formulation and JACOM against SARS-CoV-2 spike protein. J Ayurveda Integr Med 2022; 13(1): 100324.
[http://dx.doi.org/10.1016/j.jaim.2020.05.009] [PMID: 32527713]
[35]
Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: Findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials 2021; 22(1): 623.
[http://dx.doi.org/10.1186/s13063-021-05583-0] [PMID: 34526104]
[36]
Thakar A, Panara K, Goyal M, Kumari R, Sungchol K. AYUSH (Indian system of medicines) therapeutics for COVID-19: A living systematic review and meta-analysis (first update). J Integr Complement Med 2023; 29(3): 139-55.
[http://dx.doi.org/10.1089/jicm.2022.0559]
[37]
Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb–drug interaction studies with special focus on interplays: A prerequisite for integrative medicine. Porto Biomed J 2019; 4(2): e15.
[http://dx.doi.org/10.1016/j.pbj.0000000000000015] [PMID: 31595257]
[38]
Thangaraju P, Venkatesan S, Showkath Ali MK. Leprosy case detection campaign (LCDC) for active surveillance. Trop Doct 2018; 48(1): 72-3.
[http://dx.doi.org/10.1177/0049475517702059] [PMID: 28403695]